Company Valuation: Realcan Pharmaceutical Group Co., Ltd.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 7,826 5,881 6,165 4,920 4,444 4,779
Change - -24.86% 4.83% -20.19% -9.67% 7.54%
Enterprise Value (EV) 1 12,117 5,846 4,743 6,684 6,040 5,640
Change - -51.75% -18.87% 40.92% -9.64% -6.63%
P/E 24.9x 43.7x -3.32x 242x 217x 322x
PBR 1.05x 0.78x 1.14x 0.9x 0.81x 0.89x
PEG - -0.8x 0x -2x 146.48x -11.9x
Capitalization / Revenue 0.29x 0.28x 0.5x 0.61x 0.56x 0.66x
EV / Revenue 0.45x 0.28x 0.39x 0.83x 0.76x 0.77x
EV / EBITDA 7.21x 5.33x 36.2x 70x 31.4x 25.5x
EV / EBIT 8.64x 7.19x -43.6x -79.3x 196x 78x
EV / FCF -4.62x 1.03x 0.99x -1.81x -56.6x 5.15x
FCF Yield -21.7% 97.1% 101% -55.3% -1.77% 19.4%
Dividend per Share 2 0.018 0.009 - 0.013 0.011 0.002
Rate of return 0.34% 0.23% - 0.4% 0.37% 0.06%
EPS 2 0.21 0.09 -1.242 0.0135 0.0137 0.01
Distribution rate 8.57% 10% - 96.3% 80.3% 20%
Net sales 1 27,204 21,060 12,311 8,034 7,966 7,296
EBITDA 1 1,680 1,097 131.2 95.5 192.3 221.5
EBIT 1 1,402 813.4 -108.7 -84.27 30.76 72.26
Net income 1 261.3 131.2 -1,832 20.32 20.62 16.07
Net Debt 1 4,290 -34.82 -1,422 1,764 1,595 860.3
Reference price 2 5.230 3.930 4.120 3.270 2.970 3.220
Nbr of stocks (in thousands) 1,496,437 1,496,437 1,496,437 1,504,710 1,496,437 1,484,264
Announcement Date 3/30/21 4/29/22 4/28/23 4/29/24 4/23/25 4/22/26
1CNY in Million2CNY
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 666M
35.96x12.96x27.14x0.55% 1,120B
37.4x6.3x17.74x2.09% 616B
36.43x8.36x17.24x2.43% 504B
20.46x4.99x12.38x2.64% 367B
106.52x5.95x25.12x2.33% 360B
21.18x5.54x13.63x2.88% 288B
21.7x4.38x12.55x2.01% 258B
27.46x7.06x12.64x2.33% 234B
-45.63x6.99x27.07x2.11% 194B
Average 29.05x 6.95x 18.39x 2.15% 394.16B
Weighted average by Cap. 34.72x 8.20x 20.04x 1.84%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Realcan Pharmaceutical Group Co., Ltd.

Historical PBR trend

Valuation ratios - PBR - Realcan Pharmaceutical Group Co., Ltd.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Realcan Pharmaceutical Group Co., Ltd.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Realcan Pharmaceutical Group Co., Ltd.

  1. Stock Market
  2. Stocks
  3. 002589 Stock
  4. Valuation Realcan Pharmaceutical Group Co., Ltd.